Clinical Trial
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Cancer Type
Siteman Kids- Pediatrics
Protocol Number
202504174
Principal Investigator
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term risk refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Protocol Interventions
Procedure: Computed Tomography, Drug: Cyclophosphamide, Biological: Dactinomycin, Drug: Doxorubicin, Drug: Etoposide, Procedure: Magnetic Resonance Imaging, Procedure: Ultrasound Imaging, Drug: Vincristine, Procedure: X-Ray Imaging
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.